Cargando…

Immunogenicity and Safety of Influenza Vaccination in Systemic Lupus Erythematosus Patients Compared with Healthy Controls: A Meta-Analysis

OBJECTIVE: To assess the immunogenicity and safety of influenza vaccine in patients with systemic lupus erythematosus (SLE). METHODS: Relevant articles were retrieved from electronic databases. Seroprotection rate, seroconversion rate and factors that increase antibody geometric mean titer (GMT) wer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liao, Zhengfa, Tang, Hao, Xu, Xiaojia, Liang, Yaping, Xiong, Yongzhen, Ni, Jindong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4742052/ https://www.ncbi.nlm.nih.gov/pubmed/26845680 http://dx.doi.org/10.1371/journal.pone.0147856

Ejemplares similares

Is Systemic Lupus Erythematosus Associated With a Declined Immunogenicity and Poor Safety of Influenza Vaccination?: A Systematic Review and Meta-Analysis
por: Huang, Yafang, et al.
Publicado: (2016)

Immunogenicity and safety of inactivated and mRNA COVID-19 vaccines in patients with systemic lupus erythematosus
por: So, Ho, et al.
Publicado: (2022)

Safety and immunogenicity of the quadrivalent HPV vaccine in female Systemic Lupus Erythematosus patients aged 12 to 26 years
por: Soybilgic, Arzu, et al.
Publicado: (2013)

Immunogenicity and Safety of mRNA Anti-SARS-CoV-2 Vaccines in Patients with Systemic Lupus Erythematosus
por: Mormile, Ilaria, et al.
Publicado: (2022)

Immunogenicity and safety of inactivated quadrivalent influenza vaccine compared with the trivalent vaccine for influenza infection: an overview of systematic reviews
por: Carregaro, Rodrigo Luiz, et al.
Publicado: (2023)

Influenza Vaccination of Patients With Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA)
por: Stojanovich, Ljudmila
Publicado: (2006)

Immunogenicity and safety of subunit influenza vaccines in pregnant women
por: Kostinov, Mikhail P., et al.
Publicado: (2018)

Safety and immunogenicity of synchronous COVID19 and influenza vaccination
por: Baj, Andreina, et al.
Publicado: (2022)

Immunogenicity and safety of coadministration of COVID-19 and influenza vaccination
por: Wagenhäuser, Isabell, et al.
Publicado: (2023)

Skin reaction to capsaicin in patients with systemic lupus erythematosus compared to healthy controls
por: Sahebari, Maryam, et al.
Publicado: (2021)

Immunogenicity and safety of a trivalent inactivated influenza vaccine produced in Shenzhen, China
por: Mo, Zhaojun, et al.
Publicado: (2017)

COVID-19 vaccine safety during pregnancy in women with systemic lupus erythematosus
por: Giannopoulou, Nefeli, et al.
Publicado: (2023)

Linear cutaneous lupus erythematosus/discoid lupus erythematosus in an adult
por: Mao, Qiu-Xia, et al.
Publicado: (2017)

Safety, efficacy, and immunogenicity of an inactivated influenza vaccine in healthy adults: a randomized, placebo-controlled trial over two influenza seasons
por: Jackson, Lisa A, et al.
Publicado: (2010)

Clinical Efficacy and Safety of Mesenchymal Stem Cells for Systemic Lupus Erythematosus
por: Zhou, Tianbiao, et al.
Publicado: (2020)

Safety and immunogenicity of 3 seasonal trivalent influenza vaccines in the Chinese military
por: Gao, Dongqi, et al.
Publicado: (2016)

Safety and immunogenicity of an inactivated thimerosal‐free influenza vaccine in infants and children
por: Nolan, Terry, et al.
Publicado: (2009)

Immunogenicity and safety of Quadrivalent Influenza HA vaccine compared with Trivalent Influenza HA vaccine and evaluation of Quadrivalent Influenza HA vaccine batch-to-batch consistency in Indonesian children and adults
por: Fadlyana, Eddy, et al.
Publicado: (2023)

Immunogenicity and Safety of the Quadrivalent Adjuvant Subunit Influenza Vaccine in Seropositive and Seronegative Healthy People and Patients with Common Variable Immunodeficiency
por: Kostinov, Mikhail P., et al.
Publicado: (2020)

Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial
por: Houser, Katherine V., et al.
Publicado: (2022)

Immunogenicity and Safety of the COVID-19 Vaccines Compared With Control in Healthy Adults: A Qualitative and Systematic Review
por: Lau, Oscar, et al.
Publicado: (2022)

Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus
por: Cortés-Hernández, Josefina, et al.
Publicado: (2012)

Immunogenicity and Safety of MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared with a Nonadjuvanted, Quadrivalent Influenza Vaccine in Adults 50–64 Years of Age
por: Poder, Airi, et al.
Publicado: (2023)

Lupus Erythematosus
por: Gardiner, Frederick
Publicado: (1923)

Lupus Erythematosus
por: Ravogli, A.
Publicado: (1887)

Analyses of the clinical and immunological characteristics of patients with lupus erythematosus
por: Deng, Min, et al.
Publicado: (2022)

Periodontal findings in systemic lupus erythematosus patients and healthy controls
por: Al-Mutairi, Khalid D., et al.
Publicado: (2015)

A survey of systemic lupus erythematosus patients' attitudes toward influenza and pneumococcal vaccination in Southwest China
por: Chen, Yanling, et al.
Publicado: (2022)

Rituximab in Systemic Lupus Erythematosus: Transient Effects on Autoimmunity Associated Lymphocyte Phenotypes and Implications for Immunogenicity
por: Faustini, Francesca, et al.
Publicado: (2022)

Immunogenicity and Safety of an AS03-Adjuvanted H7N9 Pandemic Influenza Vaccine in a Randomized Trial in Healthy Adults
por: Madan, Anuradha, et al.
Publicado: (2016)

2554. Safety and Immunogenicity of NasoVAX, a Novel Intranasal Influenza Vaccine
por: Tasker, Sybil, et al.
Publicado: (2018)

Influenza and respiratory syncytial virus (RSV) vaccines for infants: Safety, immunogenicity, and efficacy
por: Beeler, Judy A., et al.
Publicado: (2013)

Comparison of Immunogenicity and Safety of Inactivated, Adenovirus-Vectored, and Heterologous Adenovirus-Vectored/mRNA Vaccines in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis: A Prospective Cohort Study
por: Assawasaksakul, Theerada, et al.
Publicado: (2022)

Cardiac Safety of mRNA-based Vaccines in Patients with Systemic Lupus Erythematosus and Lupus-like Disorders with a History of Myocarditis
por: Ramirez, Giuseppe A., et al.
Publicado: (2022)

Immunogenicity and safety of a trivalent inactivated influenza vaccine produced in Shenzhen, China versus a comparator influenza vaccine: a phase IV randomized study
por: Hu, Yuemei, et al.
Publicado: (2019)

PIN5 Immunogenicity and Safety of the COVID-19 Vaccines Compared to Controls in Healthy Adults: A Systematic Review
por: Lau, O., et al.
Publicado: (2021)

Vaccination of Adult Patients with Systemic Lupus Erythematosus in Portugal
por: Moraes-Fontes, Maria Francisca, et al.
Publicado: (2016)

Systemic Lupus Erythematosus Following COVID-19 Vaccination
por: Salleh, Anna Farazilah Mohd, et al.
Publicado: (2022)

Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 years or older: a randomized Phase III trial
por: Pepin, Stephanie, et al.
Publicado: (2021)

Effects of Prior Influenza Exposure on Immunogenicity of Influenza Vaccine
por: Cao, Jia-Qian, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_dcnkhdqv22osntv1erro3c081a